Cingulate Inc (CING)

$4.83 -0.11 (-2.23%)
Market Cap 66.54M
Revenue (ttm) 0.00
Net Income (ttm) -22.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 222,700
Avg Vol 617,406
Day's Range N/A - N/A
Shares Out 13.47M
Stochastic %K 31%
Beta -0.85
Analysts Strong Sell
Price Target $23.00

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In...

Industry: Biotechnology
Sector: Healthcare
Phone: 913 942 2300
Address:
1901 West 47th Place, Kansas City, United States
MR2601
MR2601 Jun. 24 at 3:00 PM
$CING is an under the radar stock with very good pipeline and ADHD drug which may get approval in 2027 after the resubmission in 2026. It may go double digit in 1 yr time.
0 · Reply
DonkeyClanbrands
DonkeyClanbrands Jun. 24 at 2:37 AM
$CING are we stuck in purgatory?
1 · Reply
biotechs2021
biotechs2021 Jun. 23 at 10:10 PM
$CING just cause.
0 · Reply
DonkeyClanbrands
DonkeyClanbrands Jun. 23 at 5:11 PM
$CING where is the video they posted a screenshot over 2 weeks ago on linkedin? Not impresive that they would post something with no material? @Bob_Coyle any insight?
1 · Reply
denhopeforbest
denhopeforbest Jun. 23 at 4:43 PM
$CING someone post the crl pls
0 · Reply
Jumpingfox
Jumpingfox Jun. 23 at 3:16 PM
$CING Had anyone actually seen the CRL? It isn’t even available in the FDA site.
0 · Reply
I_Buy_Stock
I_Buy_Stock Jun. 22 at 8:32 PM
$SLS $SPY $VOO $CING This you?
0 · Reply
jacob_Berkstein_
jacob_Berkstein_ Jun. 22 at 7:54 PM
$SLS $SPY $VOO $CING shut up BITCH
1 · Reply
denhopeforbest
denhopeforbest Jun. 22 at 4:52 PM
$CING may we get back on track with the golden cross Jacob? exactly zero shares to short. ctb will climb.
0 · Reply
Laacy
Laacy Jun. 22 at 3:05 PM
$CING fwiw a lot of orthodox Jewish groups dont believe in the state of Israel for religious reasons...
0 · Reply
Latest News on CING
Cingulate issues patent by USPTO for CTx-1301

2026-06-16T12:17:17.000Z - 8 days ago

Cingulate issues patent by USPTO for CTx-1301

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Jun 16, 2026, 8:00 AM EDT - 8 days ago

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Jun 4, 2026, 4:48 PM EDT - 19 days ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Roth sees ‘major silver lining’ in Cingulate complete response letter

2026-06-04T10:50:56.000Z - 20 days ago

Roth sees ‘major silver lining’ in Cingulate complete response letter

Cingulate issued complete response letter for CTx-1301 from FDA

2026-06-02T13:17:58.000Z - 22 days ago

Cingulate issued complete response letter for CTx-1301 from FDA

US FDA declines to approve Cingulate's ADHD drug

Jun 2, 2026, 8:08 AM EDT - 22 days ago

US FDA declines to approve Cingulate's ADHD drug

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Jun 2, 2026, 8:00 AM EDT - 22 days ago

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 26 days ago

Cingulate Proxy statement: Proxy filing

Cingulate Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 26 days ago

Cingulate Proxy statement: Proxy filing

Cingulate price target lowered to $10 from $14 at Roth Capital

2026-05-19T15:00:40.000Z - 5 weeks ago

Cingulate price target lowered to $10 from $14 at Roth Capital

Cingulate Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 5 weeks ago

Cingulate Proxy statement: Proxy filing

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Cingulate Earnings release: Q1 2026

Cingulate Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Cingulate Quarterly report: Q1 2026

Cingulate files to sell 4.21M shares of common stock for holders

2026-04-14T21:30:17.000Z - 2 months ago

Cingulate files to sell 4.21M shares of common stock for holders

Cingulate Registration statement: Registration filing

Apr 14, 2026, 8:00 AM EDT - 2 months ago

Cingulate Registration statement: Registration filing

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Apr 6, 2026, 4:34 PM EDT - 2 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Cingulate Slides: Corporate presentation

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Cingulate Slides: Corporate presentation

Cingulate Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Cingulate Registration statement: Registration filing

Cingulate price target lowered to $14 from $16 at Roth Capital

2026-03-22T22:30:08.000Z - 3 months ago

Cingulate price target lowered to $14 from $16 at Roth Capital

Cingulate Registration statement: Registration filing

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Cingulate Registration statement: Registration filing

Cingulate files to sell 3.5M shares of common stock for holders

2026-03-20T11:46:09.000Z - 3 months ago

Cingulate files to sell 3.5M shares of common stock for holders

Cingulate announces U.S. patent notice of allowance

2026-03-18T12:12:11.000Z - 3 months ago

Cingulate announces U.S. patent notice of allowance

Cingulate reports Q4 net loss $6.3M vs. $6.2M last year

2026-03-18T12:05:55.000Z - 3 months ago

Cingulate reports Q4 net loss $6.3M vs. $6.2M last year

Cingulate sees cash runway into late 4Q26

2026-03-18T12:05:40.000Z - 3 months ago

Cingulate sees cash runway into late 4Q26

Cingulate Proxy statement: Proxy Filing

Mar 18, 2026, 8:00 AM EDT - 3 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Cingulate Earnings release: Q4 2025

Cingulate Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Cingulate Annual report: Q4 2025

Why did Cingulate stock skyrocket today?

Mar 16, 2026, 1:26 PM EDT - 3 months ago

Why did Cingulate stock skyrocket today?

Cingulate Proxy statement: Proxy Filing

Mar 2, 2026, 7:00 AM EST - 4 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Feb 18, 2026, 7:00 AM EST - 4 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate files $200M mixed securities shelf

2026-01-12T22:15:20.000Z - 5 months ago

Cingulate files $200M mixed securities shelf

Cingulate Registration statement: Registration Filing

Jan 12, 2026, 7:00 AM EST - 5 months ago

Cingulate Registration statement: Registration Filing

Cingulate price target lowered to $16 from $17 at Roth Capital

2025-11-19T12:40:10.000Z - 7 months ago

Cingulate price target lowered to $16 from $17 at Roth Capital

Cingulate price target lowered to $16 from $17 at Roth Capital

2025-11-19T00:55:07.000Z - 7 months ago

Cingulate price target lowered to $16 from $17 at Roth Capital

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Nov 18, 2025, 4:27 PM EST - 7 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

2025-11-13T13:16:41.000Z - 7 months ago

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

Cingulate Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Cingulate Quarterly report: Q3 2025

Cingulate Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Cingulate Earnings release: Q3 2025

Cingulate names Downey as CCO to lead launch prep for CTx-1301

2025-11-10T13:25:38.000Z - 8 months ago

Cingulate names Downey as CCO to lead launch prep for CTx-1301

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

2025-10-28T12:27:02.000Z - 8 months ago

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Oct 23, 2025, 4:45 PM EDT - 8 months ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate price target raised to $17 from $10 at Roth Capital

2025-10-15T01:25:08.000Z - 9 months ago

Cingulate price target raised to $17 from $10 at Roth Capital

Cingulate announces FDA accepted for review the NDA for CTx-1301

2025-10-14T12:05:41.000Z - 9 months ago

Cingulate announces FDA accepted for review the NDA for CTx-1301

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Sep 17, 2025, 8:45 AM EDT - 10 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 21, 2025, 4:35 PM EDT - 10 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 19, 2025, 8:45 AM EDT - 11 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Cingulate Quarterly report: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 11 months ago

Cingulate Quarterly report: Q2 2025

Cingulate Earnings release: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 11 months ago

Cingulate Earnings release: Q2 2025

Cingulate Provides Management Team Update

Aug 15, 2025, 9:00 AM EDT - 11 months ago

Cingulate Provides Management Team Update

Cingulate Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 11 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Aug 6, 2025, 8:45 AM EDT - 11 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Cingulate Proxy statement: Proxy Filing

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

Jul 25, 2025, 8:00 AM EDT - 11 months ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

May 8, 2025, 4:30 PM EDT - 1 year ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Earnings release: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Cingulate Earnings release: Q1 2025

Cingulate Quarterly report: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Cingulate Quarterly report: Q1 2025

Cingulate Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Cingulate Annual report: Q4 2024

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Cingulate Annual report: Q4 2024

Cingulate Earnings release: Q4 2024

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Cingulate Earnings release: Q4 2024

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Cingulate Quarterly report: Q3 2024

Cingulate Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Cingulate Earnings release: Q3 2024

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Registration statement: Registration Filing

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Sep 27, 2024, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Cingulate Proxy statement: Proxy Filing

Aug 23, 2024, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

Aug 19, 2024, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 16, 2024, 12:36 PM EDT - 2 years ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15, 2024, 7:45 AM EDT - 2 years ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Aug 13, 2024, 7:45 AM EDT - 2 years ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Cingulate Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Cingulate Quarterly report: Q2 2024

Cingulate Earnings release: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Cingulate Earnings release: Q2 2024

Cingulate Proxy statement: Proxy Filing

Jul 22, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

Jul 15, 2024, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Proxy statement: Proxy Filing

Jul 12, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Jul 12, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024, 9:15 AM EDT - 2 years ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate Proxy statement: Proxy Filing

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 4:30 PM EDT - 2 years ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Jun 25, 2024, 9:20 AM EDT - 2 years ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Proxy statement: Proxy Filing

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Cingulate Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Quarterly report: Q1 2024

Cingulate Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Earnings release: Q1 2024

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 30, 2024, 5:45 AM EDT - 2 years ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Cingulate Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 16, 2024, 5:00 PM EDT - 2 years ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Cingulate Annual report: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Cingulate Annual report: Q4 2023

Cingulate Earnings release: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Cingulate Earnings release: Q4 2023

Cingulate to Attend DCAT Week 2024 in New York City

Mar 6, 2024, 6:45 AM EST - 2 years ago

Cingulate to Attend DCAT Week 2024 in New York City

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 13, 2024, 6:45 AM EST - 2 years ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 6, 2024, 4:15 PM EST - 2 years ago

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 2 years ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Cingulate Registration statement: Registration Filing

Jan 29, 2024, 7:00 AM EST - 2 years ago

Cingulate Registration statement: Registration Filing

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Cingulate Registration statement: Registration Filing

Jan 12, 2024, 7:00 AM EST - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Registration statement: Registration Filing

Nov 15, 2023, 7:00 AM EST - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Cingulate Quarterly report: Q3 2023

Cingulate Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Cingulate Earnings release: Q3 2023

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate Proxy statement: Proxy Filing

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Sep 22, 2023, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 13, 2023, 4:15 PM EDT - 3 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 3 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 11, 2023, 6:00 AM EDT - 3 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 8, 2023, 4:31 PM EDT - 3 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

MR2601
MR2601 Jun. 24 at 3:00 PM
$CING is an under the radar stock with very good pipeline and ADHD drug which may get approval in 2027 after the resubmission in 2026. It may go double digit in 1 yr time.
0 · Reply
DonkeyClanbrands
DonkeyClanbrands Jun. 24 at 2:37 AM
$CING are we stuck in purgatory?
1 · Reply
biotechs2021
biotechs2021 Jun. 23 at 10:10 PM
$CING just cause.
0 · Reply
DonkeyClanbrands
DonkeyClanbrands Jun. 23 at 5:11 PM
$CING where is the video they posted a screenshot over 2 weeks ago on linkedin? Not impresive that they would post something with no material? @Bob_Coyle any insight?
1 · Reply
denhopeforbest
denhopeforbest Jun. 23 at 4:43 PM
$CING someone post the crl pls
0 · Reply
Jumpingfox
Jumpingfox Jun. 23 at 3:16 PM
$CING Had anyone actually seen the CRL? It isn’t even available in the FDA site.
0 · Reply
I_Buy_Stock
I_Buy_Stock Jun. 22 at 8:32 PM
$SLS $SPY $VOO $CING This you?
0 · Reply
jacob_Berkstein_
jacob_Berkstein_ Jun. 22 at 7:54 PM
$SLS $SPY $VOO $CING shut up BITCH
1 · Reply
denhopeforbest
denhopeforbest Jun. 22 at 4:52 PM
$CING may we get back on track with the golden cross Jacob? exactly zero shares to short. ctb will climb.
0 · Reply
Laacy
Laacy Jun. 22 at 3:05 PM
$CING fwiw a lot of orthodox Jewish groups dont believe in the state of Israel for religious reasons...
0 · Reply
I_Buy_Stock
I_Buy_Stock Jun. 22 at 2:56 PM
$SLS $SPY $VOO $CING "I keep hearing Yiddish from underneath the floors in my apartment, but we don't have a basement"
3 · Reply
SamMusaX
SamMusaX Jun. 22 at 1:33 AM
$CING CINGULATE INC. 2026 Annual Meeting To be held Thursday, July 9, 2026 Proposal(s) For holders as of Monday, May 18, 2026. Votes can be changed until the voting deadline. Shares available: ###,### 1) Jeff Hargroves Election of Class II Director to hold office until our annual meeting of stockholders to be held in 2029 and until his successor has been duly elected: Jeff Hargroves More Details 2) To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026 More Details 3) To approve an amendment to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 625,000 shares to 2,221,126 shares More Details 4) Adjournment of Annual Meeting if necessary. My votes are in!
1 · Reply
jacob_Berkstein_
jacob_Berkstein_ Jun. 21 at 10:29 PM
$SLS $SPY $VOO $CING Israel's right to exist should not be negotiable in US-Iran talks! A deal with iran is a deal with the terrorist !
8 · Reply
jacob_Berkstein_
jacob_Berkstein_ Jun. 19 at 4:27 PM
$FOX if you have made losses here ibvest in $CING global PTR medicine platform, price target 33+ dollar
0 · Reply
jacob_Berkstein_
jacob_Berkstein_ Jun. 19 at 4:25 PM
$SLS Scam life science invest in $CING PTR platform for medecine price tagret by analystt is 33 dollar plus
3 · Reply
Bio_buyout
Bio_buyout Jun. 18 at 11:32 PM
$CING I just took a 25,000 shares position. My friends at Sellas really like this company. What are next catalysts and time frames?
4 · Reply
Roba1gonna
Roba1gonna Jun. 18 at 11:23 PM
$CING think im legit the only bullish person so prolyl down :/
1 · Reply
TheDenniSystem
TheDenniSystem Jun. 18 at 7:41 PM
$CING Gonna have to try harder then that
0 · Reply
activehybrid
activehybrid Jun. 18 at 5:19 PM
$CING above $5 is crucial for options but after today , are we going to see going down ?
0 · Reply
denhopeforbest
denhopeforbest Jun. 18 at 3:13 PM
$CING fed speak spooked the markrt. snap out of it.
0 · Reply
DonkeyClanbrands
DonkeyClanbrands Jun. 18 at 2:08 PM
$CING literally NO volume SMH
0 · Reply
CitadelCEO69
CitadelCEO69 Jun. 18 at 9:37 AM
$SLS @Steve_TheBull_Rogers never delivers any receipts, he only delivers bagged followers. This guy is way past his prime, his spite and pride is clouding his judgement. Steve why don't you start by showing us the money you allegedly made by shorting $CING and then buying puts on SLS with the same amount? Don't trade things you don't understand! This board is stacked with physicians who understand the reality of AML, understand the grief and suffering of current SOC and understand how extraordinary this drug is! I know steve won't short shares as deep down he knows he is way out of his comfort zone, gotta keep playing big boy for his exit liquidity follwers though... Spite, pride and greed will not prevail against science and humanity!
3 · Reply